SR One Capital Management Discloses 7.5% Stake in Avalyn Pharma Post-IPO
AVLN is trading near its 52-week low of $25.05 (9.6% above the low) on light trading volume (0.2× avg).
Summary
SR One Capital Management and its affiliates, including Simeon George, disclosed a 7.5% beneficial ownership stake in Avalyn Pharma Inc. following the company's initial public offering, acquired through preferred stock conversion and IPO participation.
Key Events · Ownership and Investor Activity · AVLN
-
Significant Institutional Ownership Disclosed
SR One Capital Management and its affiliates, including Simeon George, reported a 7.5% beneficial ownership stake in Avalyn Pharma Inc.
-
Post-IPO Stake Establishment
The 3,308,649 shares were acquired through the conversion of preferred stock and participation in the recent IPO at $18.00 per share, formalizing a major investor's position after the company's public debut.
-
Lock-up and Registration Rights
The reporting persons are subject to a 180-day lock-up period post-IPO, preventing immediate sales, but also hold customary registration rights for future share dispositions.
Analysis · AVLN · Life Sciences
This Schedule 13D filing formalizes the significant ownership position of SR One Capital Management, a venture capital firm, and its managing member, Simeon George, in Avalyn Pharma Inc. post-IPO. The stake, totaling 3,308,649 shares, represents 7.5% of the company's common stock. The shares were acquired through a combination of preferred stock conversion and participation in the recent IPO at $18.00 per share. While the filing indicates the shares are held for investment purposes, it also highlights a 180-day lock-up agreement preventing immediate sales and outlines future registration rights, providing a pathway for potential liquidity. This disclosure confirms substantial institutional backing for Avalyn Pharma following its public debut.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVLN was trading at $27.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $25.05 to $30.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.